Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor that arises from glial cells, leading to rapid growth and severe symptoms. It is known for its resistance to treatment and poor survival rates.
Glioblastoma Multiforme: Long-Term Safety of Temferon
We are monitoring the long-term safety and effects of Temferon in patients who have been treated for glioblastoma multiforme. This study aims to understand any potential side effects and how the disease may progress.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Have you received Temferon and completed the follow-up in the TEM-GBM_001 study?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Temferon
Autologous CD34+ Haematopoietic Stem and Progenitor Cells Transduced with a Lentiviral Vector Encoding the Interferon Alpha-2 Gene
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
IRCCS Foundation Istituto Neurologico Carlo Besta
U.O. Neurologia VIII - Neuro-oncologia Molecolare
Milan, Italy
Ospedale San Raffaele S.r.l.
U.O. Ematologia e Trapianto Midollo Osseo
Vimodrone, Italy
Sponsor: Genenta Science S.p.A.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.